Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QEL-ALLO
- Development stage
- Unknown
- Lead developer
- Quell Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
QEL-ALLO is an investigational allogeneic CAR-Treg (chimeric antigen receptor regulatory T cell) therapy being developed by Quell Therapeutics. It is part of Quell's pipeline of engineered Treg cell therapies, which are designed to harness and direct the immune-suppressive properties of regulatory T cells for the treatment of immune-mediated diseases. While specific details about QEL-ALLO’s mechanism or target indication are not provided in the available sources, it is positioned as a next-generation, off-the-shelf (allogeneic) version following Quell’s autologous CAR-Treg programs such as QEL-001. The general approach involves engineering Tregs with a chimeric antigen receptor for tissue targeting, stability modules like Foxp3 Phenotype Lock™, and safety switches to enhance persistence and control. These therapies aim to induce durable immune tolerance in settings such as transplantation or autoimmune disease[3][8].
- Other names
- QEL-ALLO
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on QEL-ALLO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QEL-ALLO.